Slate Path Capital LP Makes New Investment in Tvardi Therapeutics, Inc. $TVRD

Slate Path Capital LP purchased a new stake in Tvardi Therapeutics, Inc. (NASDAQ:TVRD) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 704,118 shares of the company’s stock, valued at approximately $16,427,000. Slate Path Capital LP owned about 7.52% of Tvardi Therapeutics at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at about $2,617,000. Marshall Wace LLP acquired a new position in Tvardi Therapeutics during the second quarter worth approximately $583,000. New York State Common Retirement Fund acquired a new position in Tvardi Therapeutics during the second quarter worth approximately $92,000. Finally, JPMorgan Chase & Co. bought a new stake in Tvardi Therapeutics in the second quarter valued at approximately $39,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on TVRD shares. Piper Sandler downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Wall Street Zen raised shares of Tvardi Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Raymond James Financial lowered shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 14th. Cantor Fitzgerald cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Finally, Barclays set a $5.00 price target on shares of Tvardi Therapeutics and gave the company an “equal weight” rating in a research note on Monday, October 13th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $55.50.

Tvardi Therapeutics Stock Up 5.6%

NASDAQ TVRD opened at $4.53 on Thursday. The firm has a 50-day moving average price of $9.63 and a two-hundred day moving average price of $21.61. Tvardi Therapeutics, Inc. has a 12-month low of $3.74 and a 12-month high of $43.65. The company has a market capitalization of $42.49 million, a P/E ratio of -0.47 and a beta of 0.11.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.24. Tvardi Therapeutics had a negative net margin of 585.37% and a negative return on equity of 282.16%.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.